HIV vaccine (TBC-3B) - Therion Biologics

Drug Profile

HIV vaccine (TBC-3B) - Therion Biologics

Alternative Names: DNA prime/MVA boost vaccine - Therion; multigenic DNA/MVA prime/boost vaccine - Therion; Recombinant MVA-fowlpox HIV-1 vaccine - Therion; Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B); TBC-3B

Latest Information Update: 25 Aug 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Therion Biologics
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 06 Feb 2008 Pharmacodynamics data from a phase I trial in HIV-1 infections presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
  • 23 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral Infections pharmacodynamics and immunogenicity sections
  • 22 Aug 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top